Nuveen’s Larimar Therapeutics LRMR Stock Holding History

Nuveen’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.73M	Buy	895,304 +220,389	+33%	+$875K	﹤0.01%	2420
2026 Q1	$3.04M	Buy	674,915 +569,733	+542%	+$2.28M	﹤0.01%	2101
2025 Q4	$401K	Hold	105,182	–	–	﹤0.01%	2962
2025 Q3	$340K	Sell	105,182 -121,820	-54%	-$457K	﹤0.01%	3025
2025 Q2	$656K	Buy	227,002 +52,214	+30%	+$121K	﹤0.01%	2787
2025 Q1	$376K	Hold	174,788	–	–	﹤0.01%	2984
2024 Q4	$676K	Hold	174,788	–	–	﹤0.01%	2877
2024 Q3	$1.14M	Sell	174,788 -36,040	-17%	-$290K	﹤0.01%	2696
2024 Q2	$1.53M	Buy	210,828 +104,598	+98%	+$801K	﹤0.01%	2510
2024 Q1	$806K	Buy	106,230 +67,738	+176%	+$528K	﹤0.01%	2783
2023 Q4	$175K	Buy	38,492 +2,837	+8%	+$9.57K	﹤0.01%	3235
2023 Q3	$141K	Hold	35,655	–	–	﹤0.01%	3088
2023 Q2	$112K	Buy	+35,655	New	+$145K	﹤0.01%	3151

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Nuveen's LRMR Position: Q2 2026 in Review

Nuveen increased its Larimar Therapeutics (LRMR) stake by 33% in Q2 2026, buying an estimated $875K and bringing the position to 895,304 shares worth $2.73M. The position accounts for ﹤0.01% of the portfolio, ranked #2420.

Nuveen first reported a position in LRMR in Q2 2023 and has held it in 13 quarters since. The position peaked at $3.04M in Q1 2026. 162 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

Nuveen held 895,304 shares of Larimar Therapeutics worth $2.73M as of Q2 2026.
Nuveen bought 220,389 Larimar Therapeutics shares in Q2 2026, an estimated $875K.
Larimar Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2420 holding.
Nuveen first reported a position in Larimar Therapeutics in Q2 2023 and has held it in 13 quarters since.
Nuveen's Larimar Therapeutics position peaked at $3.04M in Q1 2026.
162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.